Fuzhuan brick tea polysaccharides serve as a promising candidate for remodeling the gut microbiota from colitis subjects in vitro: Fermentation characteristic and anti-inflammatory activity
•FBTPS-3 could be utilized and degraded by inflammatory bowel disease (IBD) gut microbiota.•FBTPS-3 modulated the composition and structure of IBD gut microbiota.•FBTPS-3 could reverse Bacteroides and Escherichia/Shigella in IBD gut microbiota.•The metabolites of FBTPS-3 by gut microbiota showed sig...
Gespeichert in:
Veröffentlicht in: | Food chemistry 2022-10, Vol.391, p.133203-133203, Article 133203 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •FBTPS-3 could be utilized and degraded by inflammatory bowel disease (IBD) gut microbiota.•FBTPS-3 modulated the composition and structure of IBD gut microbiota.•FBTPS-3 could reverse Bacteroides and Escherichia/Shigella in IBD gut microbiota.•The metabolites of FBTPS-3 by gut microbiota showed significantly anti-inflammatory activity.•FBTPS-3 was expected as novel prebiotics for treatment of IBD.
The purified fraction 3 of polysaccharides from Fuzhuan brick tea (FBTPS-3) could attenuate the colitis and modulate the gut microbiota. However, the relationship between anti-inflammatory effect of FBTPS-3 and the gut microbiota is still unknown. Thus, the anaerobic fermentation in vitro was used to investigate the potential mechanism. FBTPS-3 could be utilized and degraded by gut microbiota from inflammatory bowel disease (IBD) subjects. Furthermore, FBTPS-3 could modulate the composition and structure of IBD gut microbiota toward to that of healthy group. FBTPS-3 showed a superior modulated effect on IBD gut microbiota by increasing Bacteroides and decreasing Escherichia/Shigella. Furthermore, the fermentation solution rather than FBTPS-3 itself showed anti-inflammatory effects on lipopolysaccharide-treated RAW264.7 macrophages, which might be due to the metabolites such as short-chain fatty acids (SCFAs). Thus, FBTPS-3 can be expected as novel prebiotics for treatment of IBD via modulating gut microbiota, and promoting the production of SCFAs. |
---|---|
ISSN: | 0308-8146 1873-7072 |
DOI: | 10.1016/j.foodchem.2022.133203 |